Published in Br J Cancer on January 01, 1997
N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol (1999) 4.20
E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol (2001) 4.04
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res (2001) 2.14
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res (2008) 1.82
The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol (2003) 1.68
Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol (1999) 1.61
Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res (2006) 1.59
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch (2008) 1.55
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res (2007) 1.35
Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch (2005) 1.33
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res (2013) 1.29
The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res (2003) 1.20
Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol (2009) 1.17
E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res (2001) 1.17
Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer (1999) 1.17
Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech (2011) 1.16
Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest (2011) 1.13
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res (2015) 1.08
Preinvasive breast cancer. Annu Rev Pathol (2010) 1.08
Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer (2000) 1.07
Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch (2006) 1.04
E-Cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci (2011) 1.02
E- and N-cadherin distribution in developing and functional human teeth under normal and pathological conditions. Am J Pathol (2002) 0.99
Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol (2007) 0.99
Ionizing radiation induces heritable disruption of epithelial cell interactions. Proc Natl Acad Sci U S A (2003) 0.99
Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr) (2013) 0.96
[Concepts and problems of lobular neoplasia]. Pathologe (2006) 0.95
E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus. Br J Cancer (1999) 0.94
Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol (2001) 0.92
Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers. Br J Cancer (2006) 0.92
Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med (2009) 0.92
Lobular breast cancer: molecular basis, mouse and cellular models. Breast Cancer Res (2015) 0.91
Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev (2016) 0.90
Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res (2012) 0.87
Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res (2008) 0.87
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. Mol Pathol (2001) 0.87
Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies. Breast Care (Basel) (2010) 0.86
Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch (2005) 0.86
Molecular drivers of lobular carcinoma in situ. Breast Cancer Res (2015) 0.86
Adhesion in mammary development: novel roles for E-cadherin in individual and collective cell migration. Curr Top Dev Biol (2015) 0.85
E-Cadherin and beta-Catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World J Surg Oncol (2005) 0.85
Altered expression of p120catenin predicts poor outcome in invasive breast cancer. J Cancer Res Clin Oncol (2010) 0.85
Lobular neoplasia: frequency and association with other breast lesions. Diagn Pathol (2011) 0.83
Cadherin cell adhesion system in canine mammary cancer: a review. Vet Med Int (2012) 0.82
In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br J Cancer (2007) 0.82
Non-operative breast pathology: lobular neoplasia. J Clin Pathol (2006) 0.81
Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med (2009) 0.81
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice? World J Clin Oncol (2014) 0.81
Aberrant E-cadherin staining patterns in invasive mammary carcinoma. World J Surg Oncol (2005) 0.81
Ductal barriers in mammary epithelium. Tissue Barriers (2013) 0.80
Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Mol Oncol (2015) 0.80
Peroxiredoxin V: A candidate breast tumor marker of population specificity. Mol Clin Oncol (2013) 0.80
Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol (2014) 0.79
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. Nat Genet (2017) 0.77
Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors. Genes Chromosomes Cancer (2014) 0.77
Synthesis, characterization, and evaluation of a novel inhibitor of WNT/β-catenin signaling pathway. Mol Cancer (2013) 0.76
[Lobular neoplasms and invasive lobular breast cancer]. Pathologe (2014) 0.76
Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Res (2016) 0.75
p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice. J Mammary Gland Biol Neoplasia (2016) 0.75
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. Breast Cancer Res (2017) 0.75
Cx26 knockout predisposes the mammary gland to primary mammary tumors in a DMBA-induced mouse model of breast cancer. Oncotarget (2015) 0.75
Cadherin cell adhesion receptors as a morphogenetic regulator. Science (1991) 13.78
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 8.75
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol (1991) 8.60
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J (1995) 4.55
Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A (1995) 4.28
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene (1996) 3.35
Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol (1994) 2.86
Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol (1993) 2.84
Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol (1993) 2.74
Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol (1993) 1.83
Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res (1994) 1.58
The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell (2001) 10.02
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 8.75
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Micrometastases and survival in stage II colorectal cancer. N Engl J Med (1998) 5.11
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J (1995) 4.55
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci (2008) 3.77
The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J (2000) 3.77
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol (2000) 3.52
A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem (1993) 3.41
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene (1996) 3.35
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res (1988) 3.31
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci (2009) 2.95
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet (2000) 2.87
Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene (2007) 2.87
Mutations of the human E-cadherin (CDH1) gene. Hum Mutat (1998) 2.84
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
alpha-Catenin-vinculin interaction functions to organize the apical junctional complex in epithelial cells. J Cell Biol (1998) 2.74
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
Rapid subchromosomal localization of cosmids by nonradioactive in situ hybridization. Cytogenet Cell Genet (1990) 2.60
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci U S A (1989) 2.54
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet (1989) 2.44
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut (1980) 2.24
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene (2010) 2.11
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 2.10
Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene (2006) 2.09
Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res (1999) 2.09
Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.03
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer (2013) 2.01
Ever since Knudson. Trends Genet (2001) 1.96
Two subsets of human alphoid repetitive DNA show distinct preferential localization in the pericentric regions of chromosomes 13, 18, and 21. Cytogenet Cell Genet (1986) 1.90
The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun (1999) 1.88
The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol (1988) 1.83
Molecular cloning of the human p120ctn catenin gene (CTNND1): expression of multiple alternatively spliced isoforms. Genomics (1998) 1.83
Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol (1999) 1.81
Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene (1991) 1.81
A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum Mol Genet (1992) 1.80
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol (2000) 1.77
Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene (2008) 1.76
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet (1999) 1.70
Detection of chromosome aneuploidy in interphase nuclei from human primary breast tumors using chromosome-specific repetitive DNA probes. Cancer Res (1988) 1.67
Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol (2003) 1.66
Sequence heterogeneity within the human alphoid repetitive DNA family. Nucleic Acids Res (1986) 1.65
DNA ploidy and survival in breast cancer patients. Cytometry (1987) 1.65
Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer (2000) 1.64
Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am J Pathol (1991) 1.63
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest (2000) 1.62
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene (2009) 1.58
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer (2004) 1.58
Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry (1991) 1.57
Nuclear localization of the p120(ctn) Armadillo-like catenin is counteracted by a nuclear export signal and by E-cadherin expression. Proc Natl Acad Sci U S A (1999) 1.56
At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics (1989) 1.55
Somatic genetic changes in human breast cancer. Biochim Biophys Acta (1994) 1.55
Immunoreactivity of proliferating cell nuclear antigen compared with bromodeoxyuridine incorporation in normal and neoplastic rat tissue. J Pathol (1992) 1.55
Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) Eur J Cancer (1999) 1.55
Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res (1989) 1.55
E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene (2001) 1.54
Flow cytometric detection of aneuploidy in colorectal adenomas. Cancer Res (1985) 1.53
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet (2001) 1.51